Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Mar;2(2):255-60.
doi: 10.1177/193229680800200214.

Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes

Loretta L Nielsen  1 , Ted Okerson, John Holcombe, Byron Hoogwerf
Affiliations

Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes

Loretta L Nielsen et al. J Diabetes Sci Technol. 2008 Mar.

Abstract

Obesity increases the risk of diabetes up to 90-fold and worsens hyperglycemia, hyperinsulinemia, insulin resistance, dyslipidemia, and nonalcoholic fatty liver disease. For patients with type 2 diabetes, weight loss can trigger improvements in all these conditions and decrease the need for glucose-lowering agents. The incretin mimetic exenatide shares many glucoregulatory properties with native glucagon-like peptide-1, including enhancement of glucose-dependent insulin secretion, glucose-dependent suppression of inappropriately high glucagon secretion, slowing of gastric emptying, and reduction of food intake in patients with type 2 diabetes. Exenatide treatment was associated with progressive weight loss in the majority of patients in clinical trials. In addition, patients with elevated markers of liver injury at baseline showed improvements. Therefore, exenatide represents a unique option for adjunctive therapy for patients with type 2 diabetes not achieving adequate glycemic control on oral antidiabetic agents, especially in patients for whom weight gain would be an additional contraindication.

Keywords: NAFLD; exenatide; obesity; type 2 diabetes.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Durable effects of exenatide on patient HbA1c and body weight. Mean ± SEM. Data from Heine 2005 (column 1), Nauck 2007 (column 2), Blonde 2006 (column 3), Buse 2007 (column 4), and Klonoff 2008 (column 5). Note that the last three references are different time point analyses of the same exenatide open-label extension study.
See this image and copyright information in PMC

References

    1. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr. 2003;22(5):331–339. - PubMed
    1. Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am. 2003;32(4):805–822. - PubMed
    1. Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab. 2004;89(6):2522–2525. - PubMed
    1. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS. Diabetes trends in the U.S.: 1990–1998. Diabetes Care. 2000;23(9):1278–1283. - PubMed
    1. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76–79. - PubMed